Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Skinvisible (SKVI) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Skinvisible (SKVI) over the last 17 years, with Q3 2025 value amounting to $645.0.

  • Skinvisible's Cash & Equivalents rose 539.22% to $645.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $645.0, marking a year-over-year increase of 539.22%. This contributed to the annual value of $10336.0 for FY2024, which is 106396.4% up from last year.
  • Skinvisible's Cash & Equivalents amounted to $645.0 in Q3 2025, which was up 539.22% from $120.0 recorded in Q2 2025.
  • Over the past 5 years, Skinvisible's Cash & Equivalents peaked at $160336.0 during Q2 2022, and registered a low of $120.0 during Q2 2025.
  • For the 5-year period, Skinvisible's Cash & Equivalents averaged around $34296.2, with its median value being $12667.0 (2021).
  • Its Cash & Equivalents has fluctuated over the past 5 years, first plummeted by 9942.63% in 2023, then surged by 106396.4% in 2024.
  • Over the past 5 years, Skinvisible's Cash & Equivalents (Quarter) stood at $66037.0 in 2021, then increased by 23.23% to $81378.0 in 2022, then tumbled by 98.91% to $888.0 in 2023, then surged by 1063.96% to $10336.0 in 2024, then crashed by 93.76% to $645.0 in 2025.
  • Its Cash & Equivalents was $645.0 in Q3 2025, compared to $120.0 in Q2 2025 and $13396.0 in Q1 2025.